---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064415"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T13:38:29.373472+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioAtla Q1 net loss $15.3M; cash $32.4M; Mec-V shows 59% 2-year OS in mKRAS NSCLC

## Summary
- Net loss $15.3M vs $23.2M YoY; R&D expenses down to $12.4M from $18.9M.
- Cash $32.4M at March 31, 2025; expects runway beyond key readouts in 1H 2026.
- BA3182 Phase 1 dose-escalation ongoing; data readout mid-2025; three patients dosed at 300 µg.
- Mec-V in mKRAS NSCLC shows 67% 1-year and 59% 2-year landmark OS (SOC <20%).
- Oz-V in HPV+ SCCHN: 45% ORR (5/11), 100% disease control; Fast Track discussions with FDA.

## SEC filing metadata
- accession: 0000950170-25-064415
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017025064415/0000950170-25-064415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017025064415/bcab-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064415
- JSON: https://secwatch.observer/filing/0000950170-25-064415.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064415.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.